To investigate whether IMS–TMZ therapy, IMS-anti-PD-1/TMZ combined therapy or anti-PD-1 monotherapy could produce such immune memory, we performed tumour re-challenge studies with the reimplantation of GL261 cells in the opposite side. Here, PDCD1 is linked to neoplasm.